Fidelity Investments’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
AIM
FCM
VPM
AVM
VCM
NAMA
KCM
Fidelity Investments's BEAM Position: Q1 2026 in Review
Fidelity Investments increased its Beam Therapeutics (BEAM) stake by 4.6% in Q1 2026, buying an estimated $15.1M and bringing the position to 12,452,199 shares worth $297M. The position accounts for 0.02% of the portfolio, ranked #693.
Fidelity Investments first reported a position in BEAM in Q1 2020 and has held it in 25 quarters since. The position peaked at $989M in Q2 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.
- Fidelity Investments held 12,452,199 shares of Beam Therapeutics worth $297M as of Q1 2026.
- Fidelity Investments bought 543,061 Beam Therapeutics shares in Q1 2026, an estimated $15.1M.
- Beam Therapeutics made up 0.02% of Fidelity Investments's portfolio in Q1 2026, its #693 holding.
- Fidelity Investments first reported a position in Beam Therapeutics in Q1 2020 and has held it in 25 quarters since.
- Fidelity Investments's Beam Therapeutics position peaked at $989M in Q2 2021.
- 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.